Transcend Capital Advisors LLC Purchases New Position in Verona Pharma PLC American Depositary Share $VRNA

Transcend Capital Advisors LLC bought a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 3,035 shares of the company’s stock, valued at approximately $287,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its position in shares of Verona Pharma PLC American Depositary Share by 2.2% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company’s stock worth $219,539,000 after purchasing an additional 73,900 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Verona Pharma PLC American Depositary Share by 1.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company’s stock worth $118,491,000 after acquiring an additional 32,748 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in shares of Verona Pharma PLC American Depositary Share by 381.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company’s stock worth $103,552,000 after acquiring an additional 1,292,575 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Verona Pharma PLC American Depositary Share by 274.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock worth $66,119,000 after acquiring an additional 763,353 shares during the period. Finally, Duquesne Family Office LLC grew its holdings in shares of Verona Pharma PLC American Depositary Share by 12.9% during the 1st quarter. Duquesne Family Office LLC now owns 1,002,080 shares of the company’s stock worth $63,622,000 after acquiring an additional 114,500 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Cowen downgraded Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. Canaccord Genuity Group downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 target price on the stock. in a report on Wednesday, July 9th. Zacks Research upgraded Verona Pharma PLC American Depositary Share to a “hold” rating in a report on Friday, August 8th. Roth Capital downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Finally, Piper Sandler downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA opened at $106.91 on Friday. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. The business’s 50 day moving average price is $106.51 and its 200-day moving average price is $94.01. Verona Pharma PLC American Depositary Share has a 52 week low of $31.09 and a 52 week high of $106.93. The stock has a market cap of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The firm had revenue of $103.14 million for the quarter, compared to analysts’ expectations of $90.41 million. Equities research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.